Nektar Therapeutics (NASDAQ:NKTR) CEO Howard Robin Sells 423 Shares

Nektar Therapeutics (NASDAQ:NKTR) CEO Howard Robin sold 423 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $73.00, for a total value of $30,879.00. Following the completion of the sale, the chief executive officer owned 75,489 shares in the company, valued at approximately $5,510,697. The trade was a 0.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Nektar Therapeutics Stock Performance

Nektar Therapeutics stock traded down $0.13 during mid-day trading on Friday, hitting $73.73. The company’s stock had a trading volume of 997,867 shares, compared to its average volume of 1,533,099. The company has a 50 day moving average of $45.81 and a 200-day moving average of $48.36. Nektar Therapeutics has a one year low of $6.45 and a one year high of $74.89. The stock has a market cap of $1.50 billion, a PE ratio of -9.25 and a beta of 1.34.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC boosted its holdings in Nektar Therapeutics by 336.9% in the first quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock worth $2,463,000 after acquiring an additional 2,807,595 shares in the last quarter. BVF Inc. IL grew its position in Nektar Therapeutics by 22.2% during the 4th quarter. BVF Inc. IL now owns 1,559,595 shares of the biopharmaceutical company’s stock worth $65,940,000 after purchasing an additional 283,000 shares during the last quarter. Vanguard Group Inc. increased its stake in Nektar Therapeutics by 30.0% during the 3rd quarter. Vanguard Group Inc. now owns 948,647 shares of the biopharmaceutical company’s stock valued at $53,978,000 after purchasing an additional 219,155 shares in the last quarter. Farallon Capital Management LLC acquired a new position in Nektar Therapeutics during the 3rd quarter valued at approximately $45,008,000. Finally, Two Seas Capital LP purchased a new position in shares of Nektar Therapeutics in the fourth quarter worth $31,506,000. 75.88% of the stock is currently owned by hedge funds and other institutional investors.

More Nektar Therapeutics News

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Zacks Research raised multiple multi‑quarter and full‑year EPS projections (FY2026 and FY2027 were revised to smaller losses), indicating improved analyst expectations for Nektar’s future results — a generally constructive signal for the stock. MarketBeat NKTR
• Positive Sentiment: Nektar announced research collaboration with UCSF to test a TNFR2‑agonist/antibody approach in multiple sclerosis — a meaningful pipeline development that could add long‑term value if clinical data are positive. MSNewsToday: UCSF, Nektar team BioWorld: TNFR2 agonism in MS
• Neutral Sentiment: An AAII piece compared Nektar to another biotech (Harmony Biosciences) as an investment choice — useful context for longer‑term investors but unlikely to move the stock materially on its own. AAII comparison article
• Negative Sentiment: Zacks cut near‑term quarter estimates for Q2 2026 (and separately trimmed Q2 2027), signaling some expected near‑term pressure to results that can weigh on sentiment. MarketBeat NKTR

Analysts Set New Price Targets

A number of brokerages recently weighed in on NKTR. BTIG Research lifted their price objective on shares of Nektar Therapeutics from $118.00 to $151.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nektar Therapeutics in a research report on Monday, December 29th. Citigroup began coverage on Nektar Therapeutics in a research report on Wednesday, November 26th. They set a “buy” rating and a $102.00 target price for the company. HC Wainwright raised their price target on Nektar Therapeutics from $135.00 to $165.00 and gave the company a “buy” rating in a research note on Tuesday, February 10th. Finally, Wall Street Zen cut Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Nektar Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $119.86.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.